1. 92O Nivolumab plus low-dose ipilimumab as first-line treatment of advanced NSCLC: Overall survival analysis of checkmate 817. (15th December 2019) Authors: Barlesi, F; Audigier-Valette, C; Felip, E; Ciuleanu, T-E; Jao, K; Rijavec, E; Urban, L; Aucoin, J-S; Zannori, C; Vermaelen, K; Frontera, O Arén; Ready, N; Curioni, A; Linardou, H; Poddubskaya, E; Fischer, J R; Pillai, R; Li, S; Acevedo, A; Paz-Ares, L Journal: Annals of oncology Issue: Volume 30(2019)Supplement 11 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. FAMU: study of the energy dependent transfer rate Λμp → μO. (November 2018) Authors: Mocchiutti, E; Bonvicini, V; Danailov, M; Furlanetto, E; Gadedjisso-Tossou, K S; Guffaanti, D; Pizzolotto, C; Rachevski, A; Stoychev, L; Vallazza, E; Zampa, G; Niemela, J; Ishida, K; Adamczak, A; Baccolo, G; Benocci, R; Bertoni, R; Bonesini, M; Chignoli, F; Clemenza, M Journal: Journal of physics Issue: Volume 1138(2018) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗